The Biopharma Report
Subscribe
Sign in
Home
Archive
About
Share this publication
The Biopharma Report
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
The Biopharma Report
The must-have biotech/pharma newsletter
Launched 8 months ago
Subscribe
Let me read it first
The Biopharma Report #006
$BIIB $RHHBY
The Biopharma Report
5
Share this post
The Biopharma Report #006
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
New
Top
The Biopharma Report #005
$RHHBY $REGN $ABBV $RGNX $NESN $MCRB
The Biopharma Report
Jul 20
9
Share this post
The Biopharma Report #005
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
The Biopharma Report #004
$SNY $ICPT
The Biopharma Report
Jul 14
6
Share this post
The Biopharma Report #004
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
Pfizer’s Ibrance Disappoints: What’s Next?
Taking a Look at the CDK4/6 Inhibitors Landscape
Jun 13
3
Share this post
Pfizer’s Ibrance Disappoints: What’s Next?
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
Agios Pharmaceuticals $AGIO
A Concise Look into the Company and its Upcoming Catalyst
Dec 26, 2021
7
Share this post
Agios Pharmaceuticals $AGIO
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
Akebia Therapeutics $AKBA
Vadadustat and the HIF-PH Inhibitors Landscape
Dec 19, 2021
9
Share this post
Akebia Therapeutics $AKBA
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
The Biopharma Report
The must-have newsletter for biotech/pharma investors and consultants.
Dec 5, 2021
12
Share this post
The Biopharma Report
thebiopharmareport.substack.com
Copy link
Twitter
Facebook
Email
The Biopharma Report
Subscribe
About
Archive
Authors
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
